Old Web
English
Sign In
Acemap
>
authorDetail
>
Katherine Hendren
Katherine Hendren
Harvard University
Population
Biology
Ovarian cancer
Cancer research
Cancer
4
Papers
58
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Abstract AS25: An adeno-associated virus (AAV) 9 vector delivering modified human mullerian inhibiting substance (MIS) as a gene therapy for ovarian cancer
2015
Clinical Cancer Research
David Pépin
Amanda Sosulski
Katherine Hendren
Li Hua Zhang
Fotini Nicolaou
Dan Wang
Guangping Gao
Patricia K. Donahoe
Show All
Source
Cite
Save
Citations (1)
AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer
2015
Proceedings of the National Academy of Sciences of the United States of America
David Pépin
Amanda Sosulski
LiHua Zhang
Dan Wang
Vinod Vathipadiekal
Katherine Hendren
Caroline Coletti
Aaron Yu
Cesar M. Castro
Michael J. Birrer
Guangping Gao
Patricia K. Donahoe
Show All
Source
Cite
Save
Citations (34)
Abstract A42: An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant c-terminal Mullerian inhibiting substance
2013
Clinical Cancer Research
David Pépin
Mien Hoeng
Fotini Nicolaou
Katherine Hendren
Leo Benedict
Amanda Sosulski
Ahmad Al-Moujahed
Demetrious Vavvas
Patricia K. Donahoe
Show All
Source
Cite
Save
Citations (2)
An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance
2013
David Pépin
Mai P. Hoang
Fotini Nicolaou
Katherine Hendren
Leo Andrew Benedict
Ahmad Al-Moujahed
Amanda Sosulski
Anna Marmalidou
Demetrios G. Vavvas
Patricia K. Donahoe
Show All
Source
Cite
Save
Citations (21)
1